Global Arthritic Therapeutic Market Size, Share & Trends Analysis Report By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others), By Product Type, By Regional Outlook and Forecast, 2023 - 2030
세계 관절염 치료제 시장 규모는 2030년까지 1,126억 달러에 달할 것으로 예상되며, 예측 기간 동안 CAGR 5.1%를 나타낼 전망입니다.
또한 보완대체요법에는 침술, 마사지 요법, 요가, 태극권, 영양 보충제, 약초 요법, 심신 요법 등 다양한 치료법이 포함됩니다. 따라서 보완대체요법에 대한 관심이 높아짐에 따라 시장이 크게 확대될 것으로 예상됩니다.
그러나 관절염 치료의 높은 비용은 환자, 특히 보험이 충분하지 않거나 자금이 부족한 환자들에게 큰 경제적 부담을 안겨줍니다. 관절염 관리의 경제적 부담은 약물 복용을 제한하고, 약물 복용을 생략하고, 필요한 의료 개입을 미루어 궁극적으로 치료 효과와 환자 결과를 손상시킬 수 있습니다. 따라서 높은 비용은 시장 성장을 둔화시킬 수 있습니다.
코로나19 팬데믹으로 인해 외래 진료, 선택적 시술, 비응급 진료 등 일상적인 의료 서비스가 중단되어 관절염 진단, 치료 시작 및 질병 모니터링이 지연되고 있으며, 코로나19 팬데믹으로 인해 전 세계 의약품 공급망에 혼란이 발생하여 생물학적 치료제를 포함한 특정 관절염 치료제의 품절과 재고 부족 및 접근이 지연되고 있습니다. 생물학적 치료제와 전문 의약품을 포함한 특정 관절염 치료제의 부족, 품절 및 공급 지연이 발생했습니다. 따라서 코로나19 팬데믹은 시장에 어느 정도 영향을 미쳤습니다.
목차
제1장 시장 범위와 조사 방법
- 시장의 정의
- 목적
- 시장 범위
- 세분화
- 조사 방법
제2장 시장 요람
제3장 시장 개요
- 서론
- 시장에 영향을 미치는 주요 요인
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 시장이 해결해야 할 과제
- Porter의 Five Forces 분석
제4장 관절염 치료 시장에서 전개되고 있는 최근 전략
제5장 세계의 관절염 치료 시장 : 용도별
- 세계의 류마티스 관절염 시장 : 지역별
- 세계의 건선성 관절염 시장 : 지역별
- 세계의 골관절염 시장 : 지역별
- 세계의 강직성 척추염 시장 : 지역별
- 세계의 기타 시장 : 지역별
제6장 세계의 관절염 치료 시장 : 제품 유형별
- 세계의 비스테로이드성 항염증제(NSAID) 시장 : 지역별
- 세계의 질환 조절 항류머티즘제(DMARD) 시장 : 지역별
- 세계의 생물제제 시장 : 지역별
- 세계의 기타 시장 : 지역별
제7장 세계의 관절염 치료 시장 : 지역별
- 북미 관절염 치료 시장
- 용도별
- 제품 유형별
- 국가별
- 미국 관절염 치료 시장
- 캐나다 관절염 치료 시장
- 멕시코 관절염 치료 시장
- 기타 북미 관절염 치료 시장
- 유럽 관절염 치료 시장
- 용도별
- 제품 유형별
- 국가별
- 독일 관절염 치료 시장
- 영국 관절염 치료 시장
- 프랑스 관절염 치료 시장
- 러시아 관절염 치료 시장
- 스페인 관절염 치료 시장
- 이탈리아 관절염 치료 시장
- 기타 유럽 관절염 치료 시장
- 아시아태평양 관절염 치료 시장
- 용도별
- 제품 유형별
- 국가별
- 중국 관절염 치료 시장
- 일본 관절염 치료 시장
- 인도 관절염 치료 시장
- 한국 관절염 치료 시장
- 싱가포르 관절염 치료 시장
- 말레이시아 관절염 치료 시장
- 기타 아시아태평양 관절염 치료 시장
- 라틴아메리카/중동 및 아프리카 관절염 치료 시장
- 용도별
- 제품 유형별
- 국가별
- 브라질 관절염 치료 시장
- 아르헨티나 관절염 치료 시장
- 아랍에미리트 관절염 치료 시장
- 사우디아라비아 관절염 치료 시장
- 남아프리카공화국 관절염 치료 시장
- 나이지리아 관절염 치료 시장
- 기타 라틴아메리카/중동 및 아프리카 관절염 치료 시장
제8장 기업 개요
- AbbVie, Inc
- Pfizer, Inc
- Amgen, Inc
- Novartis AG
- F Hoffmann-La Roche Ltd.
- Viatris, Inc
- Bausch Health Companies, Inc
- Sanofi SA
- Merck & Co, Inc.
- Bristol-Myers Squibb Company
제9장 관절염 치료 시장을 위한 성공 필수 조건
LSH
The Global Arthritic Therapeutic Market size is expected to reach $112.6 billion by 2030, rising at a market growth of 5.1% CAGR during the forecast period.
The osteoarthritis segment encompasses a diverse array of treatment modalities, including pharmacological interventions, non-pharmacological therapies, and surgical interventions. Therefore, the osteoarthritis segment captured $7,913.2 million revenue in the market in 2022. Pharmaceutical companies develop and market a range of medications for osteoarthritis, including analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and viscosupplementation agents, to provide symptom relief and improve joint function.
As the prevalence of arthritis continues to rise globally, there is a growing population of individuals affected by the disease. This expanding patient population creates a larger market for arthritis therapies, including pharmacological interventions, non-pharmacological treatments, surgical procedures, and assistive devices, driving demand for arthritis treatments, and supporting market growth. Therefore, the market is expanding significantly due to the growing prevalence of arthritis.
Additionally, complementary and alternative therapies encompass various treatment modalities, including acupuncture, massage therapy, yoga, tai chi, dietary supplements, herbal remedies, and mind-body techniques. Thus, because of the rising focus on complementary and alternative therapies, the market is anticipated to increase significantly.
However, The high cost of arthritis therapeutics places a substantial financial burden on patients, particularly those without adequate insurance coverage or limited financial resources. The financial burden of arthritis management can contribute to medication rationing, skipping doses, or preceding necessary medical interventions, ultimately compromising treatment efficacy and patient outcomes. Thus, high cost can slow down the growth of the market.
The COVID-19 pandemic disrupted routine healthcare services, including outpatient visits, elective procedures, and non-urgent medical appointments, leading to delays in arthritis diagnosis, treatment initiation, and disease monitoring. The COVID-19 pandemic disrupted global drug supply chains, leading to shortages, stockouts, and delays in the availability of certain arthritic medications, including biologic therapies and specialty drugs. Thus, the COVID-19 pandemic had a moderate effect on the market.
By Application Analysis
Based on application, the market is classified into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. The psoriatic arthritis segment acquired 12.9% revenue share in the market in 2022. Psoriatic arthritis represents a significant unmet medical need, as it affects individuals with psoriasis, a common skin condition, and can lead to progressive joint damage, disability, and impaired quality of life if left untreated.
By Product Type Analysis
By product type, the market is categorized into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics, and others. In 2022, the non-steroidal anti-inflammatory drugs (NSAIDs) segment held 38.7% revenue share in the market. NSAIDs are instrumental in managing various symptoms associated with arthritis, including pain, swelling, stiffness, and functional impairment.
By Regional Analysis
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired 23.4% revenue share in the market. Urbanization and lifestyle changes in the Asia Pacific region, including sedentary lifestyles, unhealthy diets, obesity, and physical inactivity, contribute to the rising prevalence of arthritis.
Recent Strategies Deployed in the Market
- 2023-Oct: Amgen, Inc. completed the acquisition of Horizon Therapeutics plc, a biopharmaceutical company. Through this acquisition, Horizon will help to further establish Amgen as a leader across a broader range of diseases. Furthermore, the companies will collaborate to serve even more patients worldwide who are suffering from serious illnesses.
- 2022-Oct: Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company. Through this acquisition, Pfizer enhanced its product portfolio of potential calcitonin gene-related peptide (CGRP) receptor antagonists.
- 2022-Mar: Pfizer, Inc. completed the acquisition of Arena Pharmaceuticals, Inc., a clinical-stage company. Under this acquisition, Arena Pharmaceuticals will give Pfizer access to a collection of different and promising experimental treatments in areas like stomach and intestine health, skin conditions, and heart-related issues.
- 2021-Dec: Novartis AG received approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab), which is required for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older and active juvenile psoriatic arthritis (JPsA) in patients two years and older. Cosentyx is the first biologic indicated for ERA and the only biologic treatment approved for both ERA and PsA in paediatric patients in the US. The approved paediatric dosing for Cosentyx in children and adolescents is 75 mg (15 kg or more to less than 50 kg) or 150 mg (50 kg or more).
- 2020-Oct: Merck & Co., Inc. came into an agreement with Novartis AG, a Swiss multinational pharmaceutical corporation. Under this agreement, the M6495, an anti-ADAMTS5 Nanobody intended for potential osteoarthritis (OA) therapy, was introduced. The new product is designed to be administered via self-injection under the skin, with the goal of preserving knee joint structural integrity and alleviating pain.
List of Key Companies Profiled
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Global Arthritic Therapeutic Market Report Segmentation
By Application
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Others
By Product Type
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1.Market Scope & Methodology
- 1.1Market Definition
- 1.2Objectives
- 1.3Market Scope
- 1.4Segmentation
- 1.4.1Global Arthritic Therapeutic Market, by Application
- 1.4.2Global Arthritic Therapeutic Market, by Product Type
- 1.4.3Global Arthritic Therapeutic Market, by Geography
- 1.5Methodology for the research
Chapter 2.Market at a Glance
Chapter 3.Market Overview
- 3.1Introduction
- 3.1.1Overview
- 3.1.1.1Market Composition and Scenario
- 3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
- 3.3Porter's Five Forces Analysis
Chapter 4.Recent Strategies Deployed in the Arthritic Therapeutic Market
Chapter 5.Global Arthritic Therapeutic Market, by Application
- 5.1Global Rheumatoid Arthritis Market, by Region
- 5.2Global Psoriatic Arthritis Market, by Region
- 5.3Global Osteoarthritis Market, by Region
- 5.4Global Ankylosing Spondylitis Market, by Region
- 5.5Global Others Market, by Region
Chapter 6.Global Arthritic Therapeutic Market, by Product Type
- 6.1Global Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Region
- 6.2Global Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Region
- 6.3Global Biologics Market, by Region
- 6.4Global Others Market, by Region
Chapter 7.Global Arthritic Therapeutic Market, by Region
- 7.1North America Arthritic Therapeutic Market
- 7.1.1North America Arthritic Therapeutic Market, by Application
- 7.1.1.1North America Rheumatoid Arthritis Market, by Country
- 7.1.1.2North America Psoriatic Arthritis Market, by Country
- 7.1.1.3North America Osteoarthritis Market, by Country
- 7.1.1.4North America Ankylosing Spondylitis Market, by Country
- 7.1.1.5North America Others Market, by Country
- 7.1.2North America Arthritic Therapeutic Market, by Product Type
- 7.1.2.1North America Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
- 7.1.2.2North America Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
- 7.1.2.3North America Biologics Market, by Country
- 7.1.2.4North America Others Market, by Country
- 7.1.3North America Arthritic Therapeutic Market, by Country
- 7.1.3.1US Arthritic Therapeutic Market
- 7.1.3.1.1US Arthritic Therapeutic Market, by Application
- 7.1.3.1.2US Arthritic Therapeutic Market, by Product Type
- 7.1.3.2Canada Arthritic Therapeutic Market
- 7.1.3.2.1Canada Arthritic Therapeutic Market, by Application
- 7.1.3.2.2Canada Arthritic Therapeutic Market, by Product Type
- 7.1.3.3Mexico Arthritic Therapeutic Market
- 7.1.3.3.1Mexico Arthritic Therapeutic Market, by Application
- 7.1.3.3.2Mexico Arthritic Therapeutic Market, by Product Type
- 7.1.3.4Rest of North America Arthritic Therapeutic Market
- 7.1.3.4.1Rest of North America Arthritic Therapeutic Market, by Application
- 7.1.3.4.2Rest of North America Arthritic Therapeutic Market, by Product Type
- 7.2Europe Arthritic Therapeutic Market
- 7.2.1Europe Arthritic Therapeutic Market, by Application
- 7.2.1.1Europe Rheumatoid Arthritis Market, by Country
- 7.2.1.2Europe Psoriatic Arthritis Market, by Country
- 7.2.1.3Europe Osteoarthritis Market, by Country
- 7.2.1.4Europe Ankylosing Spondylitis Market, by Country
- 7.2.1.5Europe Others Market, by Country
- 7.2.2Europe Arthritic Therapeutic Market, by Product Type
- 7.2.2.1Europe Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
- 7.2.2.2Europe Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
- 7.2.2.3Europe Biologics Market, by Country
- 7.2.2.4Europe Others Market, by Country
- 7.2.3Europe Arthritic Therapeutic Market, by Country
- 7.2.3.1Germany Arthritic Therapeutic Market
- 7.2.3.1.1Germany Arthritic Therapeutic Market, by Application
- 7.2.3.1.2Germany Arthritic Therapeutic Market, by Product Type
- 7.2.3.2UK Arthritic Therapeutic Market
- 7.2.3.2.1UK Arthritic Therapeutic Market, by Application
- 7.2.3.2.2UK Arthritic Therapeutic Market, by Product Type
- 7.2.3.3France Arthritic Therapeutic Market
- 7.2.3.3.1France Arthritic Therapeutic Market, by Application
- 7.2.3.3.2France Arthritic Therapeutic Market, by Product Type
- 7.2.3.4Russia Arthritic Therapeutic Market
- 7.2.3.4.1Russia Arthritic Therapeutic Market, by Application
- 7.2.3.4.2Russia Arthritic Therapeutic Market, by Product Type
- 7.2.3.5Spain Arthritic Therapeutic Market
- 7.2.3.5.1Spain Arthritic Therapeutic Market, by Application
- 7.2.3.5.2Spain Arthritic Therapeutic Market, by Product Type
- 7.2.3.6Italy Arthritic Therapeutic Market
- 7.2.3.6.1Italy Arthritic Therapeutic Market, by Application
- 7.2.3.6.2Italy Arthritic Therapeutic Market, by Product Type
- 7.2.3.7Rest of Europe Arthritic Therapeutic Market
- 7.2.3.7.1Rest of Europe Arthritic Therapeutic Market, by Application
- 7.2.3.7.2Rest of Europe Arthritic Therapeutic Market, by Product Type
- 7.3Asia Pacific Arthritic Therapeutic Market
- 7.3.1Asia Pacific Arthritic Therapeutic Market, by Application
- 7.3.1.1Asia Pacific Rheumatoid Arthritis Market, by Country
- 7.3.1.2Asia Pacific Psoriatic Arthritis Market, by Country
- 7.3.1.3Asia Pacific Osteoarthritis Market, by Country
- 7.3.1.4Asia Pacific Ankylosing Spondylitis Market, by Country
- 7.3.1.5Asia Pacific Others Market, by Country
- 7.3.2Asia Pacific Arthritic Therapeutic Market, by Product Type
- 7.3.2.1Asia Pacific Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
- 7.3.2.2Asia Pacific Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
- 7.3.2.3Asia Pacific Biologics Market, by Country
- 7.3.2.4Asia Pacific Others Market, by Country
- 7.3.3Asia Pacific Arthritic Therapeutic Market, by Country
- 7.3.3.1China Arthritic Therapeutic Market
- 7.3.3.1.1China Arthritic Therapeutic Market, by Application
- 7.3.3.1.2China Arthritic Therapeutic Market, by Product Type
- 7.3.3.2Japan Arthritic Therapeutic Market
- 7.3.3.2.1Japan Arthritic Therapeutic Market, by Application
- 7.3.3.2.2Japan Arthritic Therapeutic Market, by Product Type
- 7.3.3.3India Arthritic Therapeutic Market
- 7.3.3.3.1India Arthritic Therapeutic Market, by Application
- 7.3.3.3.2India Arthritic Therapeutic Market, by Product Type
- 7.3.3.4South Korea Arthritic Therapeutic Market
- 7.3.3.4.1South Korea Arthritic Therapeutic Market, by Application
- 7.3.3.4.2South Korea Arthritic Therapeutic Market, by Product Type
- 7.3.3.5Singapore Arthritic Therapeutic Market
- 7.3.3.5.1Singapore Arthritic Therapeutic Market, by Application
- 7.3.3.5.2Singapore Arthritic Therapeutic Market, by Product Type
- 7.3.3.6Malaysia Arthritic Therapeutic Market
- 7.3.3.6.1Malaysia Arthritic Therapeutic Market, by Application
- 7.3.3.6.2Malaysia Arthritic Therapeutic Market, by Product Type
- 7.3.3.7Rest of Asia Pacific Arthritic Therapeutic Market
- 7.3.3.7.1Rest of Asia Pacific Arthritic Therapeutic Market, by Application
- 7.3.3.7.2Rest of Asia Pacific Arthritic Therapeutic Market, by Product Type
- 7.4LAMEA Arthritic Therapeutic Market
- 7.4.1LAMEA Arthritic Therapeutic Market, by Application
- 7.4.1.1LAMEA Rheumatoid Arthritis Market, by Country
- 7.4.1.2LAMEA Psoriatic Arthritis Market, by Country
- 7.4.1.3LAMEA Osteoarthritis Market, by Country
- 7.4.1.4LAMEA Ankylosing Spondylitis Market, by Country
- 7.4.1.5LAMEA Others Market, by Country
- 7.4.2LAMEA Arthritic Therapeutic Market, by Product Type
- 7.4.2.1LAMEA Non-steroidal Anti-inflammatory Drugs (NSAIDs) Market, by Country
- 7.4.2.2LAMEA Disease Modified Anti-rheumatoid Drugs (DMARDs) Market, by Country
- 7.4.2.3LAMEA Biologics Market, by Country
- 7.4.2.4LAMEA Others Market, by Country
- 7.4.3LAMEA Arthritic Therapeutic Market, by Country
- 7.4.3.1Brazil Arthritic Therapeutic Market
- 7.4.3.1.1Brazil Arthritic Therapeutic Market, by Application
- 7.4.3.1.2Brazil Arthritic Therapeutic Market, by Product Type
- 7.4.3.2Argentina Arthritic Therapeutic Market
- 7.4.3.2.1Argentina Arthritic Therapeutic Market, by Application
- 7.4.3.2.2Argentina Arthritic Therapeutic Market, by Product Type
- 7.4.3.3UAE Arthritic Therapeutic Market
- 7.4.3.3.1UAE Arthritic Therapeutic Market, by Application
- 7.4.3.3.2UAE Arthritic Therapeutic Market, by Product Type
- 7.4.3.4Saudi Arabia Arthritic Therapeutic Market
- 7.4.3.4.1Saudi Arabia Arthritic Therapeutic Market, by Application
- 7.4.3.4.2Saudi Arabia Arthritic Therapeutic Market, by Product Type
- 7.4.3.5South Africa Arthritic Therapeutic Market
- 7.4.3.5.1South Africa Arthritic Therapeutic Market, by Application
- 7.4.3.5.2South Africa Arthritic Therapeutic Market, by Product Type
- 7.4.3.6Nigeria Arthritic Therapeutic Market
- 7.4.3.6.1Nigeria Arthritic Therapeutic Market, by Application
- 7.4.3.6.2Nigeria Arthritic Therapeutic Market, by Product Type
- 7.4.3.7Rest of LAMEA Arthritic Therapeutic Market
- 7.4.3.7.1Rest of LAMEA Arthritic Therapeutic Market, by Application
- 7.4.3.7.2Rest of LAMEA Arthritic Therapeutic Market, by Product Type
Chapter 8.Company Profiles
- 8.1AbbVie, Inc.
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5SWOT Analysis
- 8.2Pfizer, Inc.
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional & Segmental Analysis
- 8.2.4Research & Development Expense
- 8.2.5Recent strategies and developments:
- 8.2.5.1Acquisition and Mergers:
- 8.2.6SWOT Analysis
- 8.3Amgen, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Regional Analysis
- 8.3.4Research & Development Expenses
- 8.3.5Recent strategies and developments:
- 8.3.5.1Acquisition and Mergers:
- 8.3.6SWOT Analysis
- 8.4Novartis AG
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Segmental and Regional Analysis
- 8.4.4Research & Development Expense
- 8.4.5Recent strategies and developments:
- 8.4.5.1Trials and Approvals:
- 8.4.6SWOT Analysis
- 8.5F. Hoffmann-La Roche Ltd.
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Segmental and Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5SWOT Analysis
- 8.6Viatris, Inc.
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Segmental Analysis
- 8.6.4Research & Development Expense
- 8.6.5Recent strategies and developments:
- 8.6.5.1Trials and Approvals:
- 8.6.6SWOT Analysis
- 8.7Bausch Health Companies, Inc
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Segmental and Regional Analysis
- 8.7.4Research & Development Expense
- 8.7.5SWOT Analysis
- 8.8Sanofi S.A.
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5Recent strategies and developments:
- 8.8.5.1Partnerships, Collaborations, and Agreements:
- 8.8.6SWOT Analysis
- 8.9Merck & Co., Inc.
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental and Regional Analysis
- 8.9.4Research & Development Expenses
- 8.9.5Recent strategies and developments:
- 8.9.5.1Partnerships, Collaborations, and Agreements:
- 8.9.6SWOT Analysis
- 8.10.Bristol-Myers Squibb Company
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expenses
- 8.10.5SWOT Analysis
Chapter 9.Winning Imperatives of Arthritic Therapeutic Market
